GeoVax Labs Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $0.55
- Today's High:
- $0.5749
- Open Price:
- $0.56
- 52W Low:
- $0.51
- 52W High:
- $1.54
- Prev. Close:
- $0.555
- Volume:
- 83218
Company Statistics
- Market Cap.:
- $14.68 million
- Book Value:
- 0.649
- Revenue TTM:
- $0
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $81526
- Profit Margin:
- 0%
- Return on Assets TTM:
- -45.44%
- Return on Equity TTM:
- -85.79%
Company Profile
GeoVax Labs Inc had its IPO on 1999-04-09 under the ticker symbol GOVX.
The company operates in the Healthcare sector and Biotechnology industry. GeoVax Labs Inc has a staff strength of 14 employees.
Stock update
Shares of GeoVax Labs Inc opened at $0.56 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $0.55 - $0.57, and closed at $0.55.
This is a -0.4% slip from the previous day's closing price.
A total volume of 83,218 shares were traded at the close of the day’s session.
In the last one week, shares of GeoVax Labs Inc have slipped by -2.76%.
GeoVax Labs Inc's Key Ratios
GeoVax Labs Inc has a market cap of $14.68 million, indicating a price to book ratio of 0.4806 and a price to sales ratio of 59.0082.
In the last 12-months GeoVax Labs Inc’s revenue was $0 with a gross profit of $81526 and an EBITDA of $-19741086. The EBITDA ratio measures GeoVax Labs Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, GeoVax Labs Inc’s operating margin was 0% while its return on assets stood at -45.44% with a return of equity of -85.79%.
In Q2, GeoVax Labs Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 100%.
GeoVax Labs Inc’s PE and PEG Ratio
- Forward PE
- 10.627
- Trailing PE
- 0
- PEG
- 0
Its diluted EPS in the last 12-months stands at $-0.74 per share while it has a forward price to earnings multiple of 10.627 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into GeoVax Labs Inc’s profitability.
GeoVax Labs Inc stock is trading at a EV to sales ratio of 4.1502 and a EV to EBITDA ratio of 0.2373. Its price to sales ratio in the trailing 12-months stood at 59.0082.
GeoVax Labs Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $21.25 million
- Total Liabilities
- $4.09 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $23805
- Dividend Payout Ratio
- 0%
GeoVax Labs Inc ended 2025 with $21.25 million in total assets and $0 in total liabilities. Its intangible assets were valued at $21.25 million while shareholder equity stood at $17.16 million.
GeoVax Labs Inc ended 2025 with $0 in deferred long-term liabilities, $4.09 million in other current liabilities, 26444.00 in common stock, $-88362559.00 in retained earnings and $0 in goodwill. Its cash balance stood at $17.79 million and cash and short-term investments were $17.79 million. The company’s total short-term debt was $0 while long-term debt stood at $0.
GeoVax Labs Inc’s total current assets stands at $19.83 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $0 compared to accounts payable of $871131.00 and inventory worth $0.
In 2025, GeoVax Labs Inc's operating cash flow was $0 while its capital expenditure stood at $23805.
Comparatively, GeoVax Labs Inc paid $0 in dividends in 2025.
Other key metrics
- Current Trading Price
- $0.55
- 52-Week High
- $1.54
- 52-Week Low
- $0.51
- Analyst Target Price
- $5.4
GeoVax Labs Inc stock is currently trading at $0.55 per share. It touched a 52-week high of $1.54 and a 52-week low of $1.54. Analysts tracking the stock have a 12-month average target price of $5.4.
Its 50-day moving average was $0.57 and 200-day moving average was $0.66 The short ratio stood at 1.32 indicating a short percent outstanding of 0%.
Around 123.9% of the company’s stock are held by insiders while 607.6% are held by institutions.
Frequently Asked Questions About GeoVax Labs Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company is developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, it is also developing GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-MM02 treatment for malaria; GEO-EM01 for the treatment of fever viruses, such as Ebola, Sudan, and Marburg; GEO-LM01 for the treatment of Lassa fever. GeoVax Labs, Inc. has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; Emory University; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia.